Business

Biogen beats expectations, hikes outlook as Alzheimer’s drug Leqembi and other new products gain traction

Uptake of Biogen’s breakthrough Alzheimer’s drug, Leqembi, appears to be picking up, with roughly $40 million in sales for the quarter.

Previous post Moderna stock falls more than 10% as it slashes guidance on low EU sales, tough U.S. vaccine market
Next post Wayfair CEO likens home goods slowdown to 2008 financial crisis: ‘Customers remain cautious’

More Stories